GlassScriptPhysician profile
Mark Allen Joseph
NPI 1871560862
$2,267.43
in general payments reported to CMS, 2019-2025
21 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $77.91 · 2021: $491 · 2022: $153 · 2023: $329 · 2024: $438 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $358.51 | 2019-2025 | Clareon, Simbrinza, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.52 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $237.44 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $217.44 | 2020-2025 | Acthar |
| Bausch & Lomb Americas INC. | $183.15 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Glaukos Corporation | $121.63 | 2023-2025 | Idosetr, Istent Infinite |
| Sun Pharmaceutical Industries INC. | $113.36 | 2020-2025 | Cequa |
| Dompe US, INC. | $96.57 | 2019-2025 | Oxervate |
| Harrow Eye, LLC | $95.10 | 2024-2025 | Vevye, Iheezo |
| Ocular Therapeutix, INC. | $94.95 | 2021-2025 | Dextenza |
| Allergan, INC. | $83.35 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $72.62 | 2019-2021 | |
| Travere Therapeutics, INC. | $71.42 | 2021 | |
| Abbvie INC. | $51.89 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $43.40 | 2022-2023 | Rayone Spheric, Omidria, Rayone Aspheric |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $39.08 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $38.85 | 2021 | |
| Biotissue Holdings INC. | $34.04 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $23.66 | 2022 | |
| Oyster Point Pharma, INC. | $20.96 | 2022 | |
| Sandoz INC. | $20.49 | 2024 | Cimerli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.